SB 5668
In CommitteeSenate
Newborn screening additions
Ensuring timely, efficient, and evidence-based additions to newborn screenings.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill streamlines how Washington adds new conditions to its newborn screening panel by tying updates to the federal recommended panel and requiring formal feasibility reviews before adding new tests. It also creates a dedicated revenue account for screening-related costs and allows the public to request new screenings.
- Requires the state board of health to reestablish the newborn screening panel by July 1, 2026, including all conditions on the current state panel and the federal recommended uniform screening panel as of January 1, 2025.
- Requires the state board of health to add new conditions to the screening panel within 12 months of their addition to the federal panel—after completing a feasibility review that assesses costs, federal funding, and impact on state health programs.
- Creates a formal process for the public to request additions to the screening panel; if sufficient scientific evidence exists, a feasibility review is required before the board can consider adding the condition.
- Establishes a newborn screening revenue account in the state treasury to hold all fees collected under the screening program; only the state health secretary (or designee) may authorize spending from this account.
- Clarifies that the $8.40 fee per infant (collected from parents or birthing facilities) supports specialty clinics and sickle cell disease outreach, and that this fee is in addition to other screening-related fees.
Who is affected
- Newborn infants — Newborns in Washington State will be screened for more conditions over time as the state updates its screening panel using federal recommendations and a formal review process.
- Parents and guardians of newborns — Families may be charged a $8.40 fee per child for screening, and the fee helps fund treatment services and outreach for conditions like sickle cell disease.
- Advocates and families of children with rare genetic or metabolic conditions — Will lead to more consistent, science-based updates to which conditions are screened for, and allow public input on adding new conditions.
- Washington State Department of Health and State Board of Health — Will manage the new newborn screening revenue account and coordinate with other agencies on feasibility reviews and rulemaking.
- Specialty clinics and community organizations serving families affected by metabolic or blood disorders — Will provide treatment services and community outreach for children diagnosed through newborn screening, especially for sickle cell disease.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (4)
Tying the state panel to the federal recommended uniform panel by July 1, 2026, ensures Washington aligns with national best practices, expanding screening to additional conditions over time—potentially preventing disability or death in newborns who would otherwise go undiagnosed, especially benefiting historically underserved populations who face disparities in early diagnosis.
HealthcarePeopleRef: Sec. 3(1)(b)The public petition process for adding conditions—triggering a feasibility review when sufficient scientific evidence exists—empowers families and advocates to influence policy, increasing transparency and responsiveness to community needs, particularly for rare disease communities that have historically been excluded from decision-making.
Public SafetyPeopleRef: Sec. 3(3)The $8.40 fee is explicitly designated to fund specialty clinics and sickle cell disease outreach—targeted support for children with diagnosed conditions and their families, especially critical for sickle cell disease, which disproportionately affects Black and Latino families and has historically received inadequate public health attention.
HealthcarePeopleRef: Sec. 4(2)Establishing a dedicated newborn screening revenue account improves program predictability and accountability, ensuring fees are used for screening-related purposes and not diverted to other budget priorities—reducing risk of underfunding and supporting long-term sustainability of the program.
FinancialPeopleRef: Sec. 6
Potential Concerns (4)
The bill maintains and explicitly codifies a $8.40 per-infant screening fee, which remains a direct out-of-pocket cost for parents or birthing facilities—though it is modest, it is regressive in practice as low-income families are less able to absorb even small fees without financial strain.
FinancialRef: Sec. 2(2), Sec. 4(2)Creation of a dedicated newborn screening revenue account may improve program stability, but it also risks insulating screening from broader budgetary oversight and could reduce legislative flexibility to adjust fees or redirect funds during fiscal emergencies—potentially limiting the state’s ability to reallocate resources during downturns, indirectly affecting other public health services.
FinancialRef: Sec. 6The feasibility review requirement—including assessment of costs and federal funding—may delay or prevent addition of new conditions if federal funding is uncertain, even when scientific evidence supports screening; this could result in missed diagnoses for rare but treatable conditions, especially in underserved communities with limited access to specialty care.
Public SafetyLean peopleRef: Sec. 3(2)(a)The requirement to assess availability of diagnostic testing, treatment, and interventions before adding a condition may lead to de facto rationing—conditions lacking existing infrastructure (e.g., rare metabolic disorder clinics) may be excluded despite scientific validity, disproportionately affecting families in rural or under-resourced areas who cannot access out-of-state care.
HealthcarePeopleRef: Sec. 3(3)(c)(ii)
Who Is Most Affected
Infants benefit most from expanded screening coverage—early detection of treatable conditions can prevent severe disability or death. However, those born in rural or underserved areas may still face delays in follow-up care due to limited access to specialty clinics, even if screened.
Families face a $8.40 fee per birth, which is modest but regressive; low-income families may struggle to pay even small out-of-pocket costs. However, the fee directly funds critical services (e.g., sickle cell outreach), and expanded screening may reduce long-term care costs for diagnosed conditions.
Advocates gain formal input rights and a more transparent, science-based process for adding conditions—empowering rare disease communities. However, the feasibility review standard may still exclude conditions lacking existing treatment infrastructure, limiting real-world impact.
The Department of Health gains clearer authority and process for panel updates, reducing ad hoc decision-making. However, it also inherits administrative burdens (feasibility reviews, public petitions) without additional funding, potentially straining existing resources.
Specialty clinics (especially sickle cell programs) gain guaranteed funding from the $8.40 fee, improving service stability. However, clinics for newly added conditions may not exist yet—infrastructure gaps could limit access despite screening expansion.